Percutaneous tricuspid valve therapies: The new frontier

M Taramasso, Alberto Pozzoli, Andrea Guidotti, F Nietlispach, DT Inderbitzin, S Benussi, O Alfieri, F Maisano

Research output: Contribution to journalArticlepeer-review


Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.
Original languageEnglish
Pages (from-to)639-647
Number of pages9
JournalEuropean Heart Journal
Issue number9
Publication statusPublished - 2017


Dive into the research topics of 'Percutaneous tricuspid valve therapies: The new frontier'. Together they form a unique fingerprint.

Cite this